Lakefront Biotherapeutics (GLPGF) Profit After Tax (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Profit After Tax for 13 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Profit After Tax rose 101.27% year-over-year to $1.5 million in Q2 2026; TTM through Jun 2026 was $373.8 billion, a 374.38% increase from a year earlier, with the FY2025 full-year figure at $362.5 billion, up 352.15% from the prior year.
• Profit After Tax was $1.5 million for Q2 2026 at Lakefront Biotherapeutics, down from $17.0 million in the prior quarter.
• Over five years, Profit After Tax peaked at $374.1 billion in Q4 2025 and troughed at -$236.5 million in Q3 2025.
• A 5-year average of $37.8 billion and a median of -$6.7 million in 2022 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax surged 107816.38% in 2023 and slumped 866.98% in 2025, its largest moves.
• Over 5 years, Profit After Tax stood at -$211.4 million in 2022, then surged by 107816.38% to $227.7 billion in 2023, then sank by 65.26% to $79.1 billion in 2024, then soared by 372.83% to $374.1 billion in 2025, then sank by 100.0% to $1.5 million in 2026.
• The last three Profit After Tax figures came in at $1.5 million (Q2 2026), $17.0 million (Q1 2026), and $374.1 billion (Q4 2025), per Business Quant data.